Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Adapted Therapy and Non-invasive Monitoring for Limited Stage DLBCL
NCT03758989Phase 2Recruiting
- Sponsor
- University of Rochester
- Start
- May 2019
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Rochester. Started May 2019; status: recruiting.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03758989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03758989.